LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 18, 2013) - GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced today that the European Commission has ...

Trelegy Ellipta was approved in the European Union in November 2017 for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) who are not adequately treated by an ICS/LABA ...

Trelegy Ellipta is a combination of three molecules in a single inhaler. It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, ...

The European Commission has approved a label update to GlaxoSmithKline/Innoviva’s Relvar Ellipta, expanding the asthma therapy’s reach. The European Commission ...

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a prescription drug that’s used to treat COPD and asthma. Trelegy Ellipta comes as an inhaler. To learn ...

GSK presented data at the European Respiratory Society (ERS) Congress that show blood eosinophil levels may help predict those patients with COPD who will have a greater reduction in exacerbation ...

Some people with chronic obstructive pulmonary disease (COPD) need to use multiple inhaled medicines each day to control their symptoms. Long-acting combination inhalers that contain more than one ...

What: After word that a high-profile study fell short of its primary endpoint hit the tape yesterday, shares in Theravance crumbled by 21% today. So what: Theravance is the company behind ...

LONDON--(BUSINESS WIRE)-- GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) ...

GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO ® ELLIPTA ® (fluticasone furoate/vilanterol [FF/VI]) ...

Submission supported by pivotal CAPTAIN study demonstrating statistically significant improvement in lung function compared with the ICS/LABA, Relvar/Breo Ellipta At least 30% of asthma patients ...